Plain-English translation of NCT04439708 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying chemical markers in blood and eye fluid to better understand choroidal neovascularization—abnormal blood vessel growth at the back of the eye that causes vision loss in older adults. Currently, doctors treat this condition by blocking a protein called VEGF, but some patients don't respond well to this approach. This study will compare the chemical profiles of people with this condition to those without it, hoping to identify new clues about why the condition develops and who might benefit most from current treatments.
Age-related macular degeneration is a leading cause of blindness in developed countries, and many patients don't respond fully to current anti-VEGF treatments. Researchers believe a different biological pathway may be involved in abnormal blood vessel growth, and identifying markers of this pathway could help predict which patients will benefit from treatment and potentially lead to new therapeutic options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will visit the research site where doctors will take a blood sample and collect a small sample of fluid from inside your eye. Your eye will be examined to determine if you have the abnormal blood vessel growth. The study compares these samples between people with and without the condition to identify important biological differences. The entire process typically takes a few hours, and you may be asked to return for follow-up visits depending on your group assignment.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
France
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Enrollment target
~250 participants
Started
July 2020
Primary completion
January 2027
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Francine Behar-Cohen, Dr
Institut National de la Santé Et de la Recherche Médicale, France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.